StockData
ALX Oncology Holdings Inc logo

ALX Oncology Holdings Inc (ALXO) shareholders

ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.97−0.03 (-3.47%)

Close on Nov 18, 2026Market cap $134.14MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
76.6%
106M of 138M shares
Institutional holders
94
37 new, 11 sold out
Net institutional buying
12M
In Q2 2026
Insider trades, 12 months
1 buys · 7 sales
Net bought $4.96M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
RA Capital Healthcare Fund, L.P.
Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more
13,117,1069.90%13G (passive)Feb 2, 2026
Goodman Corey S
Joint filing with venBio Global Strategic Fund II L.P. (6.50%), venBio Global Strategic GP II, L.P. (6.50%) and 1 more
12,927,4429.99%13D (active) amendmentOct 14, 2026
Redmile Group, LLC
Joint filing with Jeremy C. Green (6.80%)
9,214,1886.80%13G (passive) amendmentMar 31, 2026
HBM Healthcare Investments (Cayman) Ltd.8,590,6926.50%13G (passive) amendmentMar 31, 2026
BlackRock, Inc.7,327,8505.40%13G (passive)Jun 30, 2026
Tang Capital Partners, LP
Joint filing with Tang Capital Management, LLC (6.30%), Kevin Tang (6.30%)
3,296,8836.30%13G (passive) amendmentDec 31, 2024
Millennium Management LLC
Joint filing with Millennium Group Management LLC (6.00%), Israel A. Englander (6.00%) and 1 more
3,188,1966.00%13G (passive) amendmentOct 17, 2025
Kevin Tang
Joint filing with Tang Capital Management, LLC (5.90%)
3,158,2655.90%13G (passive) amendmentMar 31, 2025
Millennium Group Management LLC
Joint filing with Millennium Management LLC (5.10%), Israel A. Englander (5.10%)
2,707,1515.10%13G (passive)Oct 2, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ALXOValueChange% of portfolio
Ra Capital Management, L.P.13,011,8499.41%$26.93M–0.23%
venBio Partners LLC12,884,6389.32%$26.67M–5.14%
BlackRock, Inc.7,399,5305.35%$15.32M+6,951,7310.00%
Redmile Group, LLC7,392,5045.35%$15.30M−571,6841.03%
Blackstone Inc.6,593,5434.77%$13.65M+766,9990.04%
Driehaus Capital Management LLC6,025,2404.36%$12.47M+290,6200.07%
Silverarc Capital Management, LLC5,744,7574.15%$11.89MNew1.24%
TCG Crossover Management, LLC5,655,4874.09%$11.71M−7,356,3620.28%
Vanguard Capital Management LLC4,973,4363.60%$10.30M+793,7000.00%
Vivo Capital, LLC3,184,7132.30%$6.59M–0.60%
Marshall Wace, Llp3,071,4962.22%$6.36M−685,7200.01%
5AM Venture Management, LLC3,057,3252.21%$6.33M–2.20%
Almitas Capital LLC2,938,4312.13%$6.08M−235,4031.46%
Orbimed Advisors LLC2,866,2562.07%$5.93M–0.11%
Geode Capital Management, LLC2,787,8092.02%$5.77M+2,294,3720.00%
Two Sigma Investments, LP2,178,1761.58%$4.51M+590,3430.00%
Millennium Management LLC1,543,5941.12%$3.20M−444,9650.00%
Nantahala Capital Management, LLC1,500,0001.08%$3.11MNew0.05%
State Street Corp1,498,9051.08%$3.10M+1,323,0770.00%
Acadian Asset Management LLC1,313,4900.95%$2.71M+212,4650.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202694106M76.6%37 / 2910 / 1127M16M
Q1 20266994M68.2%25 / 1812 / 1270M3M
Q4 20255729M21.1%8 / 1915 / 103M4M
Q3 20256130M22.0%8 / 1031 / 87M5M
Q2 20256129M21.0%10 / 932 / 342M8M
Q1 20258535M25.2%8 / 2630 / 92M8M
Q4 20248741M29.7%21 / 3220 / 268M13M
Q3 20249246M32.9%18 / 4021 / 3612M12M
Q2 202411249M35.2%31 / 3727 / 239M7M
Q1 202410647M33.6%23 / 2930 / 103M3M
Q4 20239346M33.4%32 / 3316 / 1416M3M
Q3 20237633M24.1%12 / 2322 / 101M2M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

59 funds held ALXO in Q2 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ALXOValue% of fundAs of
Vanguard Total Stock Market Index Fund3,642,8542.63%$7.54M0.00%Jun 30, 2026
iShares Russell 2000 ETF2,598,7481.88%$5.38M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund1,174,4850.85%$2.28M0.01%Jul 31, 2026
Vanguard Extended Market Index Fund1,164,8990.84%$2.41M0.00%Jun 30, 2026
iShares Russell 2000 Growth ETF1,013,2540.73%$2.10M0.01%Jun 30, 2026
JPMorgan U.S. Small Company Fund393,9600.28%$815.50K0.07%Jun 30, 2026
iShares Micro-Cap ETF361,7770.26%$748.88K0.05%Jun 30, 2026
Schwab Small-Cap Index Fund260,2120.19%$504.81K0.01%Jul 31, 2026
Ultra-Small Company Market Fund211,0000.15%$436.77K0.29%Jun 30, 2026
Master Small Cap Index Series201,6880.15%$417.49K0.01%Jun 30, 2026
Fidelity Extended Market Index Fund187,9070.14%$357.02K0.00%May 31, 2026
U.S. Small Cap Equity Fund146,6760.11%$284.55K0.03%Jul 31, 2026
Nuveen Small Cap Blend Index Fund143,6450.10%$278.67K0.01%Jul 31, 2026
EQ/2000 Managed Volatility Portfolio115,6940.08%$239.49K0.01%Jun 30, 2026
Fidelity Small Cap Growth Index Fund100,4980.07%$208.03K0.01%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jason LettmannCHIEF EXECUTIVE OFFICER, Director2,393,4741.73%Aug 18, 2026
Shelly WongSVP, FINANCE AND CAO87,8280.06%Aug 18, 2026
Barbara KlenckeChief Medical Officer120,0000.09%Apr 17, 2026
Jeff E. KnightChief Dev & Operating Officer––Apr 17, 2026
Harish ShantharamChief Financial Officer75,0000.05%Jan 28, 2026
Jaume PonsPRESIDENT & CSO579,3880.42%Feb 21, 2025
Corey S. GoodmanDirector, 10% owner8,453,0386.11%Feb 4, 2026
Rekha HemrajaniDirector33,0000.02%Jan 21, 2026
J. Scott GarlandDirector––Jan 21, 2026
Alan B. SandlerDirector––Jan 21, 2026
Daniel J. CurranDirector––Jan 21, 2026
Chris H. TakimotoDirector––Jan 21, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Shelly Wong
SVP, FINANCE AND CAO
Aug 17, 2026Sale−573$1.93$1.11K87,828
Jason Lettmann
CHIEF EXECUTIVE OFFICER, Director
Aug 17, 2026Sale−2,230$1.93$4.30K294,379
Shelly Wong
SVP, FINANCE AND CAO
Jul 1, 2026Sale−1,404$2.04$2.86K88,401
Shelly Wong
SVP, FINANCE AND CAO
Mar 19, 2026Sale−903$2.17$1.96K86,805
Jason Lettmann
CHIEF EXECUTIVE OFFICER, Director
Mar 19, 2026Sale−12,311$2.17$26.71K293,609
Shelly Wong
SVP, FINANCE AND CAO
Feb 18, 2026Sale−565$2.27$1.28K87,708
Jason Lettmann
CHIEF EXECUTIVE OFFICER, Director
Feb 17, 2026Tax withholding−2,201$2.27$5.00K305,920
Corey S. Goodman
Director, 10% owner
Feb 2, 2026Buy+3,184,713$1.57$5.00M8,453,038
Shelly Wong
SVP, FINANCE AND CAO
Jan 6, 2026Sale−3,925$1.11$4.36K88,273
Jason Lettmann
CHIEF EXECUTIVE OFFICER, Director
Sep 17, 2025Buy+71,163$1.08$76.86K305,121
Jason Lettmann
CHIEF EXECUTIVE OFFICER, Director
Sep 16, 2025Buy+21,070$1.07$22.54K233,958
Harish Shantharam
Chief Financial Officer
Aug 18, 2025Buy+75,000$0.78$58.50K75,000
Jason Lettmann
CHIEF EXECUTIVE OFFICER, Director
Aug 15, 2025Sale−2,382$0.64$1.52K212,888
Shelly Wong
SVP, FINANCE AND CAO
Aug 15, 2025Sale−611$0.64$39189,198
Shelly Wong
SVP, FINANCE AND CAO
Jul 7, 2025Sale−2,011$0.45$90586,809
Shelly Wong
SVP, FINANCE AND CAO
Jun 30, 2025Sale−1,532$0.43$65988,820
Jason Lettmann
CHIEF EXECUTIVE OFFICER, Director
Mar 14, 2025Award+42,000––212,270
Shelly Wong
SVP, FINANCE AND CAO
Mar 14, 2025Award+3,000––90,352
Shelly Wong
SVP, FINANCE AND CAO
Feb 19, 2025Sale−550$1.15$63387,352
Jaume Pons
PRESIDENT & CSO
Feb 19, 2025Sale−1,326$1.15$1.52K579,388
Jason Lettmann
CHIEF EXECUTIVE OFFICER, Director
Feb 19, 2025Sale−2,159$1.15$2.48K170,270
Shelly Wong
Interim CFO
Jan 6, 2025Sale−2,221$1.80$4.00K87,902
Shelly Wong
Interim CFO
Dec 30, 2024Sale−1,426$1.58$2.25K90,123
Jaume Pons
PRESIDENT & CSO
Dec 30, 2024Sale−10,796$1.58$17.06K580,714
Rekha Hemrajani
Director
Dec 2, 2024Buy+30,000$1.55$46.50K33,000
Jaume Pons
PRESIDENT & CSO
Aug 14, 2024Sale−1,937$2.58$5.00K591,510
Shelly Wong
SVP, FINANCE AND CAO
Aug 14, 2024Sale−564$2.58$1.46K91,549
Sophia Randolph
CHIEF MEDICAL OFFICER
Aug 14, 2024Sale−1,365$2.58$3.52K325,711
Jason Lettmann
CHIEF EXECUTIVE OFFICER, Director
Aug 14, 2024Tax withholding−2,191$2.58$5.65K169,429
Peter S. Garcia
CHIEF FINANCIAL OFFICER
Aug 14, 2024Tax withholding−761$2.58$1.96K121,516
Jaume Pons
PRESIDENT & CSO, Director
Jul 11, 2024Option exercise+20,000$0.99$19.80K613,447
Jaume Pons
PRESIDENT & CSO, Director
Jul 11, 2024Sale(10b5-1 plan)−20,000$7.90$158.00K593,447
Shelly Wong
SVP, FINANCE AND CAO
Jul 5, 2024Sale−1,823$5.50$10.03K92,113
Shelly Wong
SVP, FINANCE AND CAO
Jul 1, 2024Sale−1,373$5.82$7.99K93,936
Jaume Pons
PRESIDENT & CSO, Director
Jul 1, 2024Sale−10,758$5.82$62.61K593,447
Sophia Randolph
CHIEF MEDICAL OFFICER, Director
Jul 1, 2024Sale−3,273$5.82$19.05K327,076
Peter S. Garcia
CHIEF FINANCIAL OFFICER
Jun 28, 2024Tax withholding−1,789$6.03$10.79K122,277
Peter S. Garcia
CHIEF FINANCIAL OFFICER
Jun 13, 2024Buy+12,000$8.53$102.36K122,348
Peter S. Garcia
CHIEF FINANCIAL OFFICER
Jun 13, 2024Buy+12,000$8.53$102.36K122,348
Jaume Pons
PRESIDENT & CSO, Director
Jun 4, 2024Sale(10b5-1 plan)−20,000$8.43$168.60K604,205
Jaume Pons
PRESIDENT & CSO, Director
Jun 4, 2024Option exercise+20,000$0.99$19.80K624,205
Sophia Randolph
CHIEF MEDICAL OFFICER, Director
May 13, 2024Sale(10b5-1 plan)−1,797$16.67$29.96K330,349
Sophia Randolph
CHIEF MEDICAL OFFICER, Director
May 13, 2024Sale(10b5-1 plan)−10,203$15.82$161.41K332,146
Jaume Pons
PRESIDENT & CSO, Director
May 6, 2024Sale(10b5-1 plan)−20,000$15.92$318.40K604,205
Jaume Pons
PRESIDENT & CSO, Director
May 6, 2024Option exercise+20,000$0.99$19.80K624,205
Jaume Pons
PRESIDENT & CSO, Director
Apr 16, 2024Sale(10b5-1 plan)−50,000$14.20$710.00K604,205
Jaume Pons
PRESIDENT & CSO, Director
Apr 16, 2024Option exercise+25,846$0.99$25.59K654,205
Jaume Pons
PRESIDENT & CSO, Director
Apr 4, 2024Sale(10b5-1 plan)−20,000$11.15$223.00K628,359
Jason Lettmann
CHIEF EXECUTIVE OFFICER, Director
Mar 14, 2024Buy+4,400$11.31$49.76K171,620
Sophia Randolph
CHIEF MEDICAL OFFICER, Director
Feb 14, 2024Award+30,000––342,349
Jaume Pons
PRESIDENT & CSO, Director
Feb 14, 2024Award+30,000––648,359
Shelly Wong
SVP, FINANCE AND CAO
Feb 14, 2024Award+15,000––93,591
Jason Lettmann
CHIEF EXECUTIVE OFFICER, Director
Feb 14, 2024Award+60,000––167,220
Peter S. Garcia
CHIEF FINANCIAL OFFICER
Feb 14, 2024Award+25,000––110,348
Shelly Wong
SVP, Finance and CAO
Jan 4, 2024Sale−2,717$13.60$36.95K78,591
Peter S. Garcia
Chief Financial Officer
Dec 29, 2023Sale−1,893$15.04$28.47K85,348
Shelly Wong
SVP, Finance and CAO
Dec 29, 2023Sale−1,631$15.04$24.53K81,308
Sophia Randolph
Chief Medical Officer, Director
Dec 29, 2023Sale−3,128$15.04$47.05K312,349
Jaume Pons
President & CSO, Director
Dec 29, 2023Sale−7,179$15.04$107.97K618,359
Shelly Wong
SVP, Finance and CAO
Jul 25, 2023Award+26,000––81,713

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
5.81%
6M shares short
Days to cover
4.4
At 1M shares a day
Change since last report
+3.2%
From 6M shares
Short volume, 20 days
48.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ALX Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 14,854 shares on Sep 2, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Jaume Pons
Officer
Jul 11, 202420,000$135.20KJul 11, 2024Options Grant
Jaume Pons
Officer
Jun 4, 202420,000$179.20KJun 4, 2024Options Grant
Sophia Randolph
Officer
May 13, 202478,000$1.26MMay 13, 2024Restricted stock
Jaume Pons
Officer
May 6, 202420,000$307.20KMay 6, 2024Options Grant
Jaume Pons
Officer
Apr 16, 202450,000$644.50KApr 16, 2024Options Grant
Jaume Pons
Officer
Apr 4, 202420,000$216.00KApr 4, 2024Restricted Stock from Option Exercise

See a number that looks wrong?